A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
← catalyst calendarNCT07154745 · readout in 1,248 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
35estimated
Sites
20
Countries
Brazil, Canada, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-11 | actual | When the study began enrolling |
| Primary completion | 2030-01-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-04 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
- Drug: Pozelimab — also filed as REGN3918
- Drug: Cemdisiran — also filed as ALN-CC5
Primary outcome
what the primary-completion date above is the date OFPercent change in Lactate Dehydrogenase (LDH) during TP
measured From baseline to week 28
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed